FMX103 clinical trials
How each study uses FMX103 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- FMX103 minocycline foam 1.5%
- 2
Studies by the year they started
4 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses FMX103 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular RosaceaCompletedPhase 3Vyne Therapeutics Inc.NCT03276936Written as FMX103 1.5%
- A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular RosaceaCompletedPhase 3Vyne Therapeutics Inc.NCT03142451Written as FMX103 minocycline foam 1.5%
- A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular RosaceaCompletedPhase 3Vyne Therapeutics Inc.NCT04608500Written as FMX103 minocycline foam 1.5%
- Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular RosaceaCompletedPhase 2Vyne Therapeutics Inc.NCT02601963Written as FMX-103 1.5%